Demethylation demystification

Lauren Suarez, Steven D. Gore

Research output: Contribution to journalShort surveypeer-review

Abstract

The ability of theDNAmethyltransferase inhibitors (DNMTi) to induce terminal differentiation in fibroblasts was first noted by Taylor and Jones in 19791; Silverman and Holland reported hematologic improvement in patients with myelodysplastic syndrome (MDS) in 1993.2 That azacitidine improves survival in patients with high-riskMDSand acute myeloid leukemia withMDSfeatures compared with a combined comparator group of supportive care, low-dose cytarabine, and intensive cytarabine plus anthracycline, while inducing trilineage normalization in approximately 15% of patients3 makes the development of more potent, more specific drugs that behave like azacitidine imperative. The question is, how do the azanucleosides behave?.

Original languageEnglish (US)
Pages (from-to)1488-1489
Number of pages2
JournalBlood
Volume121
Issue number9
DOIs
StatePublished - Feb 28 2013

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Fingerprint Dive into the research topics of 'Demethylation demystification'. Together they form a unique fingerprint.

Cite this